Pancreatic Cancer Research

ResearcherCancer Research UKActive in the last 2 years

Tim Maughan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0580-5065; OpenAlex author ID A5088658336. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers

Papers 10

  1. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK. Co-author DOI 10.1016/j.clon.2024.05.012↗
  2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  3. Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expans… Co-author DOI 10.1136/bmjopen-2022-068906↗
  4. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-020-01120-z↗
  5. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Co-author DOI 10.1053/j.gastro.2021.04.044↗
  6. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  7. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pa… Co-author DOI 10.1038/bjc.2017.95↗
  8. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.03.021↗
  9. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.08.026↗
  10. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Last author DOI 10.1016/s1470-2045(13)70021-4↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Somnath Mukherjee · 10 shared papers, 2013–2024 · strength 0.99
  2. Eric E. O’Neill · 5 shared papers, 2016–2024 · strength 0.50
  3. Chris N Hurt · 6 shared papers, 2013–2024 · strength 0.49
  4. James S. Good · 2 shared papers, 2023–2024 · strength 0.36
  5. Killian Nugent · 2 shared papers, 2023–2024 · strength 0.36
  6. S. Teoh · 2 shared papers, 2023–2024 · strength 0.36
  7. M. Hawkins · 3 shared papers, 2016–2024 · strength 0.28
  8. Christopher Mark Jones · 2 shared papers, 2021–2024 · strength 0.27
  9. Ganesh Radhakrishna · 3 shared papers, 2013–2024 · strength 0.27
  10. Pippa G. Corrie · 2 shared papers, 2019–2024 · strength 0.24
  11. Frances W. Willenbrock · 2 shared papers, 2021 · strength 0.21
  12. Daniel Llwyd Hughes · 2 shared papers, 2021 · strength 0.21
  13. Harpreet Singh Wasan · 2 shared papers, 2013–2024 · strength 0.19
  14. D. Holyoake · 1 shared paper, 2024 · strength 0.16
  15. Thankamma Ajithkumar · 1 shared paper, 2024 · strength 0.16
  16. Ross Allen Abrams · 3 shared papers, 2013–2017 · strength 0.14
  17. Zenobia D’Costa · 1 shared paper, 2021 · strength 0.10
  18. Simone Lanfredini · 1 shared paper, 2021 · strength 0.10
  19. Michael Eyres · 1 shared paper, 2021 · strength 0.10
  20. Victoria Y. Strauss · 1 shared paper, 2019 · strength 0.08
  21. Thomas Baptist Brunner · 1 shared paper, 2016 · strength 0.05
  22. Mike Partridge · 1 shared paper, 2016 · strength 0.05
  23. Emmanouil Fokas · 1 shared paper, 2016 · strength 0.05
  24. James Matthew Wilson · 1 shared paper, 2016 · strength 0.05
  25. Colin Johnson · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.